First round of mass drug administration in Haiti successful
A mass drug administration to eliminate lymphatic filariasis in Port-au-Prince, Haiti, was successful, with 71% taking the medication, according to recent data.
“WHO defines adequate mass drug administration coverage as 65% or better,” the researchers wrote in the Morbidity and Mortality Weekly Report. “The first mass drug administration in Port-au-Prince was conducted from November 2011 through 2012. In all, 71% of persons swallowed the tablets.”
WHO estimated that 120 million people globally were infected with lymphatic filariasis in 2010, and Haiti was one of four countries still endemic. In 2000, WHO called for the elimination of the disease by 2020, leading to annual mass drug administration. By 2011, at least one round of mass drug administration of albendazole (Albenza, Amedra Pharmaceuticals) and diethylcarbamazine (Hetrazan, Lederle) had been issued to all endemic areas in Haiti except for Port-au-Prince.
The researchers evaluated coverage in Port-au-Prince by conducting a stratified, three-stage cluster-sample survey in seven strata: internally displaced person (IDP) camps in six communes comprised one stratum, and non-IDP camp households in each of the six communes comprised six strata. A total of 6,345 adults answered for themselves and/or others in the household about taking the tablets, and 71% (95% CI, 69-74) had taken the drugs.
Another 1,976 completed a knowledge, attitudes and practices survey. The researchers found that 88% of the respondents knew about the mass drug administration before it began. Only half of the people who did not hear about it in advance took the tablets, compared with 74% of people who did hear about it in advance.
“[The coverage] demonstrates that despite substantial obstacles posed by recent natural disasters and public health emergencies, Haiti has taken an important step toward meeting the challenge of lymphatic filariasis elimination,” the researchers wrote. “Future mass drug administration efforts should incorporate strategies that were identified in this analysis as potentially important to increase coverage and sustain program success.”
Disclosure: The researchers report no relevant financial disclosures.